Strand Therapeutics Receives IND Clearance for Programmable mRNA Therapy STX-001 to Treat Solid Tumors

Strand Therapeutics announced the US FDA has cleared its Investigational New Drug (IND) application to initiate a Phase I, first-in-human trial of STX-001, a multi-mechanistic synthetic self-replicating mRNA technology that expresses an IL-12 cytokine for an extended period, directly into the tumor microenvironment.